Statera Biopharma Inc (STAB)

$0.00 0.00 (N/A)
Market Cap 1,000.00
Revenue (ttm) 1.49M
Net Income (ttm) -101.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,835.57%
Debt to Equity Ratio 0.00
Volume 300
Avg Vol 20,178
Day's Range N/A - N/A
Shares Out 13.34M
Stochastic %K 0%
Beta -0.07
Analysts Strong Buy
Price Target N/A

Company Profile

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, inf...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 613 8802
Address:
2580 East Harmony Road,, Suite 316, Fort Collins, United States
scottcod
scottcod Jan. 21 at 11:55 PM
$STAB In January 2026, Statera Biopharma (STAB) reportedly received European Patent EP3206708. Patent Details and Scope Title: "Methods and Compositions for the Treatment of...". While the full title in recent snippets is often truncated, it pertains to Statera’s broader focus on Toll-like Receptor (TLR) pathways and immunotherapies. Core Technology: The patent likely covers compositions related to Statera's proprietary platform for rebalancing the immune system, specifically targeting indications like autoimmune diseases, neutropenia, or viral infections (such as COVID-19). Strategic Value: Securing this patent in the European Union provides Statera with intellectual property protection in up to 39 member states, enabling potential licensing deals or partnerships essential for its financial recovery. $TIVC
3 · Reply
Unfazed22
Unfazed22 Dec. 23 at 9:49 PM
$TIVC Just opened a strong position at $1.89. Plan to hold at least 2 years and maybe longer. Hoping, hoping, hoping Entolimod will go stratospheric. I'm also holding $STAB.
1 · Reply
scottcod
scottcod Dec. 11 at 7:31 PM
$STAB Big news from TIVC today in regard to advancement of Entolimod and potentially other STAB molecules @swishnetster @nu2thezu
1 · Reply
scottcod
scottcod Nov. 26 at 4:04 AM
$STAB When moon?
1 · Reply
M202209
M202209 Sep. 15 at 12:03 AM
$STAB Perhaps after TIVC brings the drugs to market, STAB will return to NASDAQ.
1 · Reply
swishnetster
swishnetster Aug. 18 at 3:02 PM
$STAB Wake me up at $10 per share. Dreaming. Nevermind.
2 · Reply
swishnetster
swishnetster Aug. 13 at 4:06 PM
$STAB Hopien Hopian however you spell it I would mainline it .
0 · Reply
nu2thezu
nu2thezu Jul. 28 at 1:34 PM
$STAB https://news.biobuzz.io/2025/07/16/coeptis-therapeutics-announces-intent-to-acquire-tlr5-agonist-platform-including-clinical-stage-asset-entolimod-from-statera-biopharma/
1 · Reply
swishnetster
swishnetster Jul. 22 at 5:56 PM
$STAB 100,000 at .0001 is $10. ? Who chipped in?
0 · Reply
swishnetster
swishnetster May. 1 at 2:31 PM
$STAB Any thoughts on TIVC and a BUY at $4.38 10:30am may 1.
1 · Reply
Latest News on STAB
No data available.
scottcod
scottcod Jan. 21 at 11:55 PM
$STAB In January 2026, Statera Biopharma (STAB) reportedly received European Patent EP3206708. Patent Details and Scope Title: "Methods and Compositions for the Treatment of...". While the full title in recent snippets is often truncated, it pertains to Statera’s broader focus on Toll-like Receptor (TLR) pathways and immunotherapies. Core Technology: The patent likely covers compositions related to Statera's proprietary platform for rebalancing the immune system, specifically targeting indications like autoimmune diseases, neutropenia, or viral infections (such as COVID-19). Strategic Value: Securing this patent in the European Union provides Statera with intellectual property protection in up to 39 member states, enabling potential licensing deals or partnerships essential for its financial recovery. $TIVC
3 · Reply
Unfazed22
Unfazed22 Dec. 23 at 9:49 PM
$TIVC Just opened a strong position at $1.89. Plan to hold at least 2 years and maybe longer. Hoping, hoping, hoping Entolimod will go stratospheric. I'm also holding $STAB.
1 · Reply
scottcod
scottcod Dec. 11 at 7:31 PM
$STAB Big news from TIVC today in regard to advancement of Entolimod and potentially other STAB molecules @swishnetster @nu2thezu
1 · Reply
scottcod
scottcod Nov. 26 at 4:04 AM
$STAB When moon?
1 · Reply
M202209
M202209 Sep. 15 at 12:03 AM
$STAB Perhaps after TIVC brings the drugs to market, STAB will return to NASDAQ.
1 · Reply
swishnetster
swishnetster Aug. 18 at 3:02 PM
$STAB Wake me up at $10 per share. Dreaming. Nevermind.
2 · Reply
swishnetster
swishnetster Aug. 13 at 4:06 PM
$STAB Hopien Hopian however you spell it I would mainline it .
0 · Reply
nu2thezu
nu2thezu Jul. 28 at 1:34 PM
$STAB https://news.biobuzz.io/2025/07/16/coeptis-therapeutics-announces-intent-to-acquire-tlr5-agonist-platform-including-clinical-stage-asset-entolimod-from-statera-biopharma/
1 · Reply
swishnetster
swishnetster Jul. 22 at 5:56 PM
$STAB 100,000 at .0001 is $10. ? Who chipped in?
0 · Reply
swishnetster
swishnetster May. 1 at 2:31 PM
$STAB Any thoughts on TIVC and a BUY at $4.38 10:30am may 1.
1 · Reply
swishnetster
swishnetster Apr. 28 at 2:23 PM
$STAB I attempted to average down and my account required me to call somebody. Never did so my question is. Can I buy this now? Should I average down? Will this ever trade? Seems like a great gamble. Oh, the call somebody may have meant a "shrink" lol
1 · Reply
scottcod
scottcod Apr. 22 at 1:32 PM
$STAB https://www.businesswire.com/news/home/20250422218401/en/Tivic-Health-Reports-White-House-Briefing-and-FDA-Meetings-Secured-Positive-Interest-in-Potential-Military-and-Defense-Applications-of-Its-Product-Candidates
1 · Reply
Unfazed22
Unfazed22 Apr. 8 at 8:30 PM
I'm starting to wish $STAB and $TIVC would merge. https://www.investing.com/news/sec-filings/tivic-health-expands-license-with-statera-biopharma-93CH-3966651
1 · Reply
Unfazed22
Unfazed22 Apr. 7 at 4:18 PM
$STAB I bought this during the pandemic at $52.03 and it looks like I'm gonna get fucked big time. Definitely a "no" vote for me.
2 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 6:41 PM
$STAB Immunotherapy play with potential. AIMS platform looks promising. Watching STAT-201 Crohn's trial closely. Might take small position if financials stabilize. superb article: https://beyondspx.com/article/statera-biopharma-stab-building-an-innovative-immunotherapy-pipeline-to-address-unmet-medical-needs
0 · Reply
swishnetster
swishnetster Feb. 26 at 8:59 PM
$STAB Michael H, could you give us (shareholders) any kind of update? Good for you on job but what about us?
1 · Reply
scottcod
scottcod Feb. 25 at 9:57 PM
$STAB https://www.stocktitan.net/news/TIVC/tivic-health-names-biotech-industry-veteran-michael-k-handley-to-plqic59spbc4.html
1 · Reply
scottcod
scottcod Feb. 14 at 4:07 AM
$STAB https://www.businesswire.com/news/home/20250212860402/en/Tivic-Health-Acquires-Exclusive-Worldwide-Rights-to-Phase-III-TLR5-Agonist-from-Statera-Biopharma
1 · Reply
Unfazed22
Unfazed22 Feb. 11 at 5:24 AM
$STAB Web site is back up after about a week (last time it was down for a month or so if I remember right). Apparently, this company is trying to stay alive although the obstacles must be daunting - especially with interest rates so high. It likely needs a large cash infusion...but from where? Neither bullish nor bearish - just numb from it. Could be a years-long wait to see what happens - good or bad. It seems like a coin toss at this point.
1 · Reply
Unfazed22
Unfazed22 Feb. 4 at 5:00 PM
$STAB Still trading on OTC but web site is suspended again.
1 · Reply
scottcod
scottcod Feb. 4 at 12:43 AM
$STAB Wonder if this trial is for Stat-201? Dated Oct 1, 2024. Phase 3. https://www.crohnscolitisfoundation.org/a-phase-3-multi-center-study-to-evaluate-the-pharmacokinetics-efficacy-and-safety-of
2 · Reply